Aldeyra Therapeutics (NASDAQ:ALDX) Shares Pass Below 200-Day Moving Average – Time to Sell?

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX)’s share price passed below its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $5.17 and traded as low as $5.15. Aldeyra Therapeutics shares last traded at $5.20, with a volume of 764,825 shares changing hands.

Aldeyra Therapeutics News Roundup

Here are the key news stories impacting Aldeyra Therapeutics this week:

• Positive Sentiment: HC Wainwright sharply upgraded near?term forecasts: Q4 2026 EPS was raised from $0.02 to $0.27 and FY2026 was lifted from ($0.35) to ($0.15), with a smaller raise for Q1 2026 (from ($0.15) to ($0.13)). Those changes suggest the analyst now sees a nearer path to breakeven/profitability, which can be a material positive for a small biotech. MarketBeat: ALDX analyst updates
• Neutral Sentiment: HC Wainwright published a FY2030 estimate of $1.04 EPS — a long?dated projection that provides a favorable long-term view but is distant and dependent on product launches/market adoption, so it’s less likely to drive near?term price action. MarketBeat: ALDX long-term estimate
• Negative Sentiment: HC Wainwright also trimmed several estimates: Q2 2026 slightly down (from ($0.15) to ($0.16)), Q3 2026 cut (from ($0.08) to ($0.13)), FY2027 lowered (from $0.11 to $0.08), and FY2028/FY2029 projections reduced (FY2028: $0.95 ? $0.79; FY2029: $1.25 ? $1.08). These downgrades temper enthusiasm by lowering peak earnings expectations and signal continued execution or commercial risk. MarketBeat: ALDX estimate cuts
• Neutral Sentiment: Short?interest reports posted in early March show zero reported short shares (data appears anomalous/placeholder), so there’s no clear short?squeeze signal from those filings. Treat the short?interest data as not actionable until clarified. MarketBeat: ALDX short interest

Analyst Ratings Changes

Separately, BTIG Research reiterated a “buy” rating and issued a $9.00 price target on shares of Aldeyra Therapeutics in a report on Monday, November 10th. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $9.50.

Aldeyra Therapeutics Price Performance

The firm has a market capitalization of $288.86 million, a PE ratio of -8.42 and a beta of 0.97. The business has a 50-day simple moving average of $5.01 and a 200-day simple moving average of $5.17.

Aldeyra Therapeutics (NASDAQ:ALDX) last issued its quarterly earnings results on Friday, February 27th. The biotechnology company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.03. On average, research analysts expect that Aldeyra Therapeutics, Inc. will post -0.92 earnings per share for the current year.

Institutional Trading of Aldeyra Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the stock. King Wealth Management Group purchased a new stake in shares of Aldeyra Therapeutics during the 2nd quarter worth $46,000. Caption Management LLC raised its holdings in Aldeyra Therapeutics by 110.6% in the second quarter. Caption Management LLC now owns 12,664 shares of the biotechnology company’s stock worth $49,000 after purchasing an additional 132,358 shares in the last quarter. Inspirion Wealth Advisors LLC bought a new position in Aldeyra Therapeutics in the fourth quarter worth about $52,000. Global Retirement Partners LLC purchased a new stake in shares of Aldeyra Therapeutics during the fourth quarter valued at about $52,000. Finally, BNP Paribas Financial Markets boosted its holdings in shares of Aldeyra Therapeutics by 36.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 10,610 shares of the biotechnology company’s stock valued at $55,000 after buying an additional 2,859 shares in the last quarter. Institutional investors own 59.71% of the company’s stock.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapies for immune-mediated diseases. The company’s research efforts center on targeted alkenals, a class of reactive aldehyde species that play a key role in inflammatory pathways. By selectively modulating these pathways, Aldeyra aims to address both ocular and systemic indications with high unmet medical need.

The company’s lead product candidate, reproxalap, is being investigated in several ophthalmic disorders, including dry eye disease, allergic conjunctivitis and non-infectious anterior uveitis.